Bicycle Therapeutics Newsroom

Morgan Stanley Maintains Bicycle Therapeutics(BCYC.US) With Hold Rating, Maintains Target Price $30

Moomoo NewsDec 13 18:31 ET · Ratings

Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Cuts Target Price to $32

Moomoo NewsDec 13 16:32 ET · Ratings

ADRs End Higher; WISeKey International Holding Ltd. Climbs 139%

Dow JonesDec 13 16:31 ET

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT NewswiresDec 13 15:59 ET

Sector Update: Health Care

MT NewswiresDec 13 15:32 ET

Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump

MT NewswiresDec 13 13:53 ET

Bicycle Therapeutics' Latest Trial Results Raise Questions -- Market Talk

WSJDec 13 13:19 ET

B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17

BenzingaDec 13 12:38 ET · Ratings

Bicycle Therapeutics Down Over 35%, on Pace for Largest Percent Decrease Since April 2022 -- Data Talk

Dow JonesDec 13 10:50 ET

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

BenzingaDec 13 08:53 ET

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

BenzingaDec 13 07:50 ET

We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash Wisely

Yahoo FinanceDec 13 07:39 ET

Express News | Bicycle Therapeutics PLC: Dose Selection and Topline Data From Phase 2/3 Duravelo-2 Trial Planned for 2H 2025

ReutersDec 12 18:31 ET

Express News | Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging Nectin4 Gene Amplification

ReutersDec 12 18:30 ET

Bicycle Therapeutics Expands Clinical Advisory Board With Three Distinguished Global Oncology Experts

BusinesswireDec 10 07:00 ET

European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading

MT NewswiresNov 27 11:08 ET

Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsNov 26 06:31 ET · Ratings

Positive Outlook on Bicycle Therapeutics Driven by Promising Data and Upcoming Updates

TipRanksNov 26 06:25 ET

Bicycle Therapeutics Plans To Present Data At SABCS; Abstract Outlines Data Showing Enhanced Anti-Tumor Activity Of Zelenectide Pevedotin Monotherapy In Triple-negative Breast Cancer Patients With NECTIN4 Gene Amplification

BenzingaNov 25 17:34 ET

Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

BusinesswireNov 25 17:30 ET